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Overexpression of a membrane-associated target on tumor or immune cells or of a factor 
in the tumor microenvironment is a major determinant if a patient can be treated with a 
monoclonal antibody against such target. Target expression is often judged on small tissue 
biopsies, which does not take into account that there may be significant intra- and 
intertumoral heterogeneity of expression. This is particularly true of diffuse intrinsic pontine 
glioma (DIPG), a paediatric glial tumour of the brainstem for which surgical resection is not 
possible. Significant heterogeneity in genetic mutations has been shown in studies studying 
the diffuse spread of these tumours across whole brain autopsy specimens [1;2]. Besides 
gene mutations affecting target expression, tumor targeting of monoclonal antibodies is a 
driven by a complex set of factors, resulting in heterogeneity of tumoral uptake of 
monoclonal antibodies. The affinity of the antibody for its target is relevant, but also target 
accessibility which is associated e.g. with tumor  perfusion and intratumoral pressure are of 
pivotal importance for an antibody to even reach its target. Earlier work on tumor targeting 
of the anti-Carbonic Anhydrase IX monoclonal antibody girentuximab has shown large 
variability of targeting of the radiolabeled antibody to the tumor antigen within resected 
primary renal cell cancer specimens, using immunoSPECT [3]. More recently, ImmunoPET 
studies in breast cancer patients by Gebhart et al. have shown, that large differences in 
tumor targeting of trastuzumab can be observed between patients, but also between 
metastases in an individual patient [4]. An additional strength of immunoPET is the 
assessment of the accessibility of a target beyond expression in multidrug treatment 
regimens. Desar et al. showed that treatment of patients with metastatic renal cell cancer 
with sorafenib resulted in a significant decrease of radiolabeled bevacizumab uptake in the 
tumor. Although ex-vivo assessment showed that expression of VEGF-A, the target for 
bevacuzimab, remained intact, the destruction of the tumor neovasculature prevented 
bevacuzimab to bind to its target [5].  
In the report by Veldhuijzen van Zanten et al. in this issue of The Journal of Nuclear 
Medicine [6], direct histologic validation of imaging results in a child with DIPG became 
possible, because the patient participated in a protocol with Zr-89-bevacizumab immunoPET 
only days prior to her untimely death and because the parents subsequently consented to 
an autopsy. Despite being a case report of a single patient, the availability of a recent MRI 
scan, a Zr-89-bevacizumab PET/CT, and post-mortem extensive immunohistochemistry in 
combination with Zr-89 tissue counting within a very short period of time resulted in a 
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unique opportunity to assess the in-vivo imaging results without significant bias of due to 
treatment effects or tumor progression.  
The 70% lower in-vivo uptake of Zr-bevacizumab in small tumors is an important 
observation. Thus, the well-known caveats of partial volume effects in small lesions 
(resulting in underestimation of tumoral Zr-89 bevacizumab uptake) as well the persisting 
blood pool activity (resulting in overestimation of tumoral Zr-89 bevacizumab uptake) do 
result in a net underestimation of tumor uptake, which needs to factored in when decisions 
on drug doses are derived from imaging results. Obviously when using small, fast clearing 
radiolabeled molecules the impact of underestimated tumor targeting due to partial volume 
effects will be even higher. 
It must be appreciated that bevacizumab binds to VEGF, which is a soluble target with a 
relatively short half life. Thus, underestimation of VEGF content in tissue samples may have 
occurred due to wash-out, resulting in low, nonspecific findings. Using In-111-bevacuzimab 
immunoSPECT in patients with colorectal liver metastases, also a lack of correlation was 
reported between the level of anti-VEGF antibody accumulation and the level of VEGF-A 
expression in the tissue as determined by in situ hybridization and ELISA [7]. It was 
concluded that that this may be due to the inability to visualize the soluble VEGF₁₂₁ isoform. 
It was also postulated that enhanced vascular permeability in tumors may play a role in 
nonspecific bevacuzimab targeting . Nevertheless, Veldhuijzen van Zanten et al. did observe 
higher Zr-89-bevacizumab targeting to areas of microvascular proliferation. Although this 
may indicate an additional target of bevacizumab, it may very well be that both the Zr-89-
bevacizumab targeting and the microvascular proliferation are the result of high local VEGF 
levels in-vivo. It is notable however that this observation did not explain all areas of 
heterogeneous uptake across the specimen, and therefore further exploration of the 
microenvironment in which DIPG cells growth and infiltrate are warranted. Recent elegant 
studies have shown a remarkable co-option of normal neuronal signalling by DIPG cells 
[8,9], highlighting the complexity of cell-cell interactions during tumour progression. This 
particular case was also unusual given it’s apparent lack of the highly prevalent histone H3 
K27M mutation. What these H3 wild-type tumours represent within the pathogenesis of 
DIPG is not clear, and extension of the present insightful studies across further tumours 
within the newly recognised diagnostic entity of ‘diffuse midline glioma with H3K27 
mutation’ will be extremely valuable. 
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In conclusion, extensive ex-vivo verification of non-invasive imaging-based assessment of 
target expression reveals important additional information, underpinning the strengths and 
challenges of molecular imaging as a tool for “in-vivo immunohistochemistry”. This 
especially holds true for conditions where obtaining tissue is not straightfoward, such as 
brain tumours. Veldhuijzen van Zanten et al. elegantly demonstrated that the untimely 
death of a very young patient with pontine glioma did result in unique and important 
scientific information. 
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